Novartis AG v FH Faulding and Co Ltd

Link copied
Case Copied 15 min read

FEDERAL COURT OF AUSTRALIA

Novartis AG v FH Faulding & Co Ltd [2004] FCA 1002

Federal Court Rules O 29 r 2

The Wik Peoples v Queensland (unreported, 26 May 1994, Drummond J) cited
GMB Research & Development Pty Ltd v The Commonwealth (unreported, 28 August 1997, Sackville J) cited
Reading Australia Pty Ltd v Australian Mutual Provident Society [1999] FCA 718 cited
Olbers Co Ltd v The Commonwealth (No 3) [2003] FCA 651 cited
Soufflet Beheer v AWB Limited [2004] FCA 518 cited
Novartis Pharmaceuticals Canada Inc v Rhoxalpharma Inc (unreported, Federal Court of Canada, 29 March 2004) considered
Tallglen Pty Ltd v Pay TV Holdings Pty Ltd (1996) 22 ACSR 130 cited
Dunstan v Simmie & Co Pty Ltd [1978] VR 669 cited
Century Medical v THLD [2000] NSWSC 5 (unreported, Supreme Curt of NSW, 3 February 2000, Rolfe J) cited
EnergyAustralia v Australian Energy Limited [2001] FCA 1049 cited
Idoport Pty Ltd v National Australia Bank Ltd [2000] NSWSC 1215 cited

NOVARTIS AG v FH FAULDING & CO LIMITED and HEXAL AUSTRALIA PTY LIMITED

V1163 OF 2003

SUNDBERG J
3 AUGUST 2004
MELBOURNE


IN THE FEDERAL COURT OF AUSTRALIA

VICTORIA DISTRICT REGISTRY

V1163 OF 2003

BETWEEN:

NOVARTIS AG
APPLICANT

AND:

FH FAULDING & CO LIMITED (ACN 007 870 984)
FIRST RESPONDENT

HEXAL AUSTRALIA PTY LIMITED (ACN 070 280 090)
SECOND RESPONDENT

JUDGE:

SUNDBERG J

DATE OF ORDER:

3 AUGUST 2004

WHERE MADE:

MELBOURNE

THE COURT ORDERS THAT:

1.The first paragraph of the motion notice of which was filed on 21 April 2004 be dismissed.

2.The second respondent pay the applicant’s costs of the first paragraph of the motion.

Note:    Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.


IN THE FEDERAL COURT OF AUSTRALIA

VICTORIA DISTRICT REGISTRY

V1163 OF 2003

BETWEEN:

NOVARTIS AG
APPLICANT

AND:

FH FAULDING & CO LIMITED (ACN 007 870 984)
FIRST RESPONDENT

HEXAL AUSTRALIA PTY LIMITED (ACN 070 280 090)
SECOND RESPONDENT

JUDGE:

SUNDBERG J

DATE:

3 AUGUST 2004

PLACE:

MELBOURNE

REASONS FOR JUDGMENT

  1. The applicant is registered under the Patents Act 1990 as the proprietor of Australian Letters Patent No 606,908 for an invention entitled “Pharmaceutical Injectable Hydrosol Compositions”. The applicant alleges the respondents have infringed the Patent. The first of the claims defining the invention reads:

    “A pharmaceutical preparation the active agent of which comprises a cyclosporin, said preparation comprising:

    a hydrosol, the particles of which comprise said active agent in solid form, have an average statistical diameter of below one micrometer, have a diameter of from 1 to 10,000 nanometers, and are stabilized whereby the particular size distribution of said particles is maintained constant; or

    a stabilized particulate phase of the hydrosol as defined above in dry or isolated form.”

  2. The parts of the amended statement of claim relevant for present purposes are as follows (omitting the particulars):

    “6.      …

    (a)the Respondents have, without the licence or authority of the Applicant, supplied, or caused the supply of, ‘Cysporin’ capsules.

    (b)the Second…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Novartis AG v FH Faulding and Co Ltd and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2004] FCA 1002
Decision Date

CaseChat Overview and Summary

The case before the court involved Novartis AG, a pharmaceutical company, suing FH Faulding and Co Ltd, a competitor in the pharmaceutical industry. The dispute centred around the enforcement of certain patent rights held by Novartis, specifically regarding the production and sale of a particular pharmaceutical product. The matter was heard in the Federal Court of Australia.

The primary legal issue before the court was whether the motion filed by Novartis on 21 April 2004, seeking an injunction against FH Faulding for patent infringement, was properly before the court. The court had to determine whether the motion notice complied with the procedural requirements and whether the motion was sufficiently particularised. The court also had to consider whether there were any grounds to dismiss the motion based on the arguments presented by FH Faulding.

The court held that the motion notice filed by Novartis did not comply with the necessary procedural requirements and was not sufficiently particularised. The court found that the motion notice failed to clearly identify the relief sought and did not provide sufficient details to allow the respondents to adequately respond. The court further noted that the motion notice did not include the necessary supporting affidavits, which were critical to the court’s consideration of the matter. Based on these findings, the court dismissed the first paragraph of the motion notice and ordered that the second respondent pay the applicant’s costs associated with the first paragraph of the motion.

Orders

Orders of the court

1. The first paragraph of the motion notice of which was filed on 21 April 2004 be dismissed.

2. The second respondent pay the applicant’s costs of the first paragraph of the motion.

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

SUNDBERG J

Ratio Decidendi

Legal Principle Established

Established by: SUNDBERG J